- •Mistral Large 2512 argues HOLD because LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technical assertion withheld pending a checked measurement. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
- •What changed: LLY cleared the $1186.61 resistance barrier and is now trading above the 4h resistance level of $1206.94. The FDA approval of Onswik (September 24, 2026) was announced, adding to the catalyst momentum. Technical assertion withheld pending a checked measurement.
LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technical assertion withheld pending a checked measurement. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
The original thesis of a catalyst-driven swing toward $1220-$1250 remains intact. Price has broken above the $1186.61 resistance barrier that was the original premortem concern, and fresh catalysts (Onswik FDA approval, Foundayo adoption data) have reinforced the fundamental case. Technical assertion withheld pending a checked measurement.
Technical assertion withheld pending a checked measurement. Fresh catalysts (Sep 24 Onswik FDA approval on top of Inluriyo/Verzenio and Mounjaro) keep the fundamental engine intact, and LLY's +3.28% session vs a flat-to-down SPY shows genuine relative strength with XLV confirmation. Stop at $1140 is untouched and target $1240 remains feasible via the LVN gap above $1206.
No model argued for EXIT.
- →Price fails to hold above the $1206.94 resistance level, reverses below $1185.88 support, and invalidates the breakout, closing the path to the original target.
Individual Model Review
Technical assertion withheld pending a checked measurement. Fresh catalysts (Sep 24 Onswik FDA approval on top of Inluriyo/Verzenio and Mounjaro) keep the fundamental engine intact, and LLY's +3.28% session vs a flat-to-down SPY shows genuine relative strength with XLV confirmation. Stop at $1140 is untouched and target $1240 remains feasible via the LVN gap above $1206.
Technical assertion withheld pending a checked measurement. Fresh catalysts (Sep 24 Onswik FDA approval on top of Inluriyo/Verzenio and Mounjaro) keep the fundamental engine intact, and LLY's +3.28% session vs a flat-to-down SPY shows genuine relative strength with XLV confirmation. Stop at $1140 is untouched and target $1240 remains feasible via the LVN gap above $1206.
▼ Click to expandThe broad regime flipped from calm/bullish to No Edge/bearish with narrowing breadth, and a dense HIGH-impact macro calendar (PCE, GDP, payrolls) lands Sep 30-Oct 2, raising the odds of a risk-off reversal. Technical assertion withheld pending a checked measurement.
▼ Click to expandThe original thesis of a catalyst-driven swing toward $1220-$1250 remains intact. Price has broken above the $1186.61 resistance barrier that was the original premortem concern, and fresh catalysts (Onswik FDA approval, Foundayo adoption data) have reinforced the fundamental case. Technical assertion withheld pending a checked measurement.
The original thesis of a catalyst-driven swing toward $1220-$1250 remains intact. Price has broken above the $1186.61 resistance barrier that was the original premortem concern, and fresh catalysts (Onswik FDA approval, Foundayo adoption data) have reinforced the fundamental case. Technical assertion withheld pending a checked measurement.
▼ Click to expandTechnical assertion withheld pending a checked measurement. The $1206.94 4h resistance is the next barrier before the target, and a rejection there could trigger a pullback that invalidates the breakout. The risk/reward from current levels is tighter than at entry with only 4.3% to target versus 2.0% to the nearest support.
▼ Click to expandLLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technical assertion withheld pending a checked measurement. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technical assertion withheld pending a checked measurement. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
▼ Click to expandThe position could be threatened if LLY fails to hold above the $1206.94 resistance level and breaks below $1185.88 support, signaling a failed breakout. Broader market weakness, particularly in the Healthcare sector, or a reversal of recent catalysts could also undermine the thesis. If the stop at $1140 is breached, the risk/reward profile would deteriorate significantly.
▼ Click to expandRun Summary
Intraday discovery triggered reanalysis on LLY. Verdict: HOLD (0/3 EXIT). Conviction: 77.